title: Triple therapy for corneal neovascularization: a case report.
abstract: OBJECTIVE
  To investigate the effect of the combination of photodynamic therapy with verteporfin and subconjunctival bevacizumab and triamcinolone acetonide on corneal neovascularization secondary to corneal graft failure.
  
  
  METHODS
  A patient with extensive deep and superficial corneal neovascularization underwent same day triple therapy with subconjunctival bevacizumab (1.25 mg), subconjunctival triamcinolone acetonide (40 mg), and photodynamic therapy with verteporfin (fluence 50 J/cm², irradiance 300 mW/cm²).
  
  
  RESULTS
  A complete angiographic new vessel regression was obtained and was discernible starting 7 days after combination therapy. Three months after treatment, an initial new-vessel sprout was noted. Triple therapy was then repeated. No angiographic evidence of corneal neovascularization was detectable for the entire 6-month follow-up duration.
  
  
  CONCLUSIONS
  Triple therapy may offer a promising tool in the treatment of corneal neovascularization.
authors.affiliation: Department of Ophthalmology, University of Udine, Udine - Italy.
authors.forename: Daniele
authors.initials: D
authors.lastname: Veritti
authors.forename: Stefano
authors.initials: S
authors.lastname: Vergallo
authors.forename: Paolo
authors.initials: P
authors.lastname: Lanzetta
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000068258:Bevacizumab; D003131:Combined Modality Therapy; D016510:Corneal Neovascularization / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D004359:Drug Therapy, Combination; D005451:Fluorescein Angiography; D005938:Glucocorticoids / Q000627:therapeutic use*; D006084:Graft Rejection / Q000150:complications; D006801:Humans; D008297:Male; D010778:Photochemotherapy; D017319:Photosensitizing Agents / Q000627:therapeutic use; D011166:Porphyrins / Q000627:therapeutic use; D014222:Triamcinolone Acetonide / Q000627:therapeutic use*; D000077362:Verteporfin; D014792:Visual Acuity / Q000502:physiology
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D005938:Glucocorticoids; D017319:Photosensitizing Agents; D011166:Porphyrins; D000077362:Verteporfin; D000068258:Bevacizumab; D014222:Triamcinolone Acetonide